Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SNX29 antisense RNA 3 (SNX29-AS3) is a non-coding RNA transcribed from the strand opposite the SNX29 gene locus, and is categorized as a long non-coding RNA natural antisense transcript (NAT), also known as antisense RNA. Antisense RNAs like SNX29-AS3 typically regulate the expression of their sense gene (in this case SNX29, Sorting nexin 29) through complementary base pairing to SNX29 mRNA, leading to inhibition of transcript translation, degradation of target mRNA, or local chromatin and epigenetic modification. The precise biological function and disease associations of SNX29-AS3 are not well-characterized; the majority of known research is on the SNX29 protein-coding gene, which has roles in lipid metabolism, reproduction, and neurodevelopment[1][3][4][2][6]. There are no known approved drugs or clinical biomarkers directly associated with SNX29-AS3. Notes on correctness: SNX29-AS3 does not appear to be a classical "therapeutic target" such as a receptor, enzyme, or transporter. Instead, it is a non-coding regulatory RNA. Current biomedical research on SNX29 mainly focuses on the protein-coding gene and not on specific antisense RNAs; published information on "SNX29 antisense RNA 3" is lacking, and there is no evidence that it is a well-established molecular target for drugs or diagnostics. This entry is largely inferential and its status as a canonical or validated locus is uncertain. If more detailed structural or functional data are needed, the SNX29 gene/protein itself should be considered.
Regulation of mRNA stability or translation by RNA-RNA hybridization; may recruit chromatin modifiers for epigenetic changes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SNX29 antisense RNA 3 (SNX29-AS3).